A Study of the Association between Psychotropic Drugs and Cognitive Dysfunction in Patients with Schizophrenia

Aditi Chaudhari, Mazumdar Kaustubh, Shobha Nair, S. Anukarthika, Divya Ramadas
2019 Indian Journal of Mental Health(IJMH)  
Cognitive deficits among patients with schizophrenia are now recognized as being widely prevalent and one of the most disabling aspects of the illness, as they are associated with poor functional outcomes. Psychotropic medications and benzodiazepines, which are often used in these patients could impact cognition as could the extrapyramidal side-effects. Yet, here are hardly any Indian studies on the subject. The aim of this study was to determine whether cognitive dysfunction among patients
more » ... among patients with schizophrenia is associated with extrapyramidal symptoms, anticholinergic burden of psychotropic drugs and benzodiazepine dosage Methodology: 40 clinically stable, out-patients suffering from schizophrenia, without any pre-existing neurological disorders between the ages of 18 to 60 years, who had been compliant with medications were selected. Extrapyramidal symptoms (EPS) were assessed using the modified Simpson-Angus scale, anticholinergic burden (ACB) was evaluated using the Anticholinergic burden scale. The benzodiazepine dosage was noted. Cognition was assessed using the Stroop Color and Word Test and the Wisconsin Card sorting test. The correlations between scores on EPS and ACB and neuropsychological tests were carried out using partial correlations controlling for positive and negative symptoms. Results: There were no significant associations noted between extrapyramidal symptoms, anticholinergic burden, benzodiazepine dosage and performance on the neurocognitive tests used. Conclusion: Methodological differences make it difficult to construct comparisons across studies but there is some evidence to support our findings.
doi:10.30877/ijmh.6.4.2019.323-332 fatcat:cku6rw7uffb5flrj6zsojaj7vu